Research backs use of myAirvo device for COPD, F&P says

 - 
Friday, April 20, 2018

AUCKLAND, New Zealand – Fisher & Paykel Healthcare says new research that has been published in the International Journal of COPD shows significant benefits of nasal high flow therapy for COPD patients using its myAirvo device. A randomized controlled trial in Denmark investigated the long-term effects of nasal high flow therapy for COPD patients already being treated with long-term oxygen therapy. The trial showed statistically significant results, including a significant reduction in the exacerbation rate of patients. It also showed a reduction in hospitalization rates, less breathlessness, better mobility and lower carbon dioxide retention levels for chronic patients. The trial followed 200 patients with COPD on long-term oxygen for 16 hours or more per day over a year. As a result of the positive outcomes of the trial, a larger multi-center trial has begun.